First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 45; no. Supplement_1
Main Authors Gabrielsen, A, Feng, Z, Fu, J, Ueckert, S, Egnell, L, Wikstrom, J, Wei, W, Chen, G, Friend, R, Zhan, H, Liang, Z, Gao, S, Gan, L
Format Journal Article
LanguageEnglish
Published 28.10.2024
Online AccessGet full text

Cover

More Information
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehae666.3327